Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer

A case report and review of the literature

Krittiya Korphaisarn, Jonathan M. Loree, Van Nguyen, Ryanne Coulson, Vijaykumar Holla, Beate C. Litzenburger, Ken Chen, Gordon Mills, Dipen M. Maru, Funda Meric-Bernstan, Kenna R.Mills Shaw, Scott Kopetz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial response that lasted 27 months. Mutational status was extensively evaluated to identify potential alterations that might play a role as predictive markers for this unusual event. A poorly characterized but nontransforming mutation in Fms-like tyrosine kinase 4 (FLT4) was present in the tumor. Prior to and at the time of clinical progression, we found amplification of fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR), loss of the FLT4 mutation, and gain of KIT proto-oncogene receptor tyrosine kinase (KIT) G961S suggesting potential roles in acquired resistance.

Original languageEnglish (US)
Pages (from-to)57882-57888
Number of pages7
JournalOncotarget
Volume8
Issue number34
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Rectal Neoplasms
Vascular Endothelial Growth Factor Receptor-1
Mutation
Receptor, Fibroblast Growth Factor, Type 1
Proto-Oncogenes
Receptor Protein-Tyrosine Kinases
Oncogenes
Epidermal Growth Factor Receptor
Sarcoma
Therapeutics
regorafenib
Neoplasms

Keywords

  • Biomarker
  • Metastatic colorectal cancer
  • Regorafenib
  • Response
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Korphaisarn, K., Loree, J. M., Nguyen, V., Coulson, R., Holla, V., Litzenburger, B. C., ... Kopetz, S. (2017). Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: A case report and review of the literature. Oncotarget, 8(34), 57882-57888. https://doi.org/10.18632/oncotarget.18357

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer : A case report and review of the literature. / Korphaisarn, Krittiya; Loree, Jonathan M.; Nguyen, Van; Coulson, Ryanne; Holla, Vijaykumar; Litzenburger, Beate C.; Chen, Ken; Mills, Gordon; Maru, Dipen M.; Meric-Bernstan, Funda; Shaw, Kenna R.Mills; Kopetz, Scott.

In: Oncotarget, Vol. 8, No. 34, 01.01.2017, p. 57882-57888.

Research output: Contribution to journalArticle

Korphaisarn, K, Loree, JM, Nguyen, V, Coulson, R, Holla, V, Litzenburger, BC, Chen, K, Mills, G, Maru, DM, Meric-Bernstan, F, Shaw, KRM & Kopetz, S 2017, 'Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: A case report and review of the literature', Oncotarget, vol. 8, no. 34, pp. 57882-57888. https://doi.org/10.18632/oncotarget.18357
Korphaisarn, Krittiya ; Loree, Jonathan M. ; Nguyen, Van ; Coulson, Ryanne ; Holla, Vijaykumar ; Litzenburger, Beate C. ; Chen, Ken ; Mills, Gordon ; Maru, Dipen M. ; Meric-Bernstan, Funda ; Shaw, Kenna R.Mills ; Kopetz, Scott. / Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer : A case report and review of the literature. In: Oncotarget. 2017 ; Vol. 8, No. 34. pp. 57882-57888.
@article{ce87742859ba44d0a30e4b0f6079b741,
title = "Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: A case report and review of the literature",
abstract = "We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial response that lasted 27 months. Mutational status was extensively evaluated to identify potential alterations that might play a role as predictive markers for this unusual event. A poorly characterized but nontransforming mutation in Fms-like tyrosine kinase 4 (FLT4) was present in the tumor. Prior to and at the time of clinical progression, we found amplification of fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR), loss of the FLT4 mutation, and gain of KIT proto-oncogene receptor tyrosine kinase (KIT) G961S suggesting potential roles in acquired resistance.",
keywords = "Biomarker, Metastatic colorectal cancer, Regorafenib, Response, Survival",
author = "Krittiya Korphaisarn and Loree, {Jonathan M.} and Van Nguyen and Ryanne Coulson and Vijaykumar Holla and Litzenburger, {Beate C.} and Ken Chen and Gordon Mills and Maru, {Dipen M.} and Funda Meric-Bernstan and Shaw, {Kenna R.Mills} and Scott Kopetz",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18357",
language = "English (US)",
volume = "8",
pages = "57882--57888",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "34",

}

TY - JOUR

T1 - Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer

T2 - A case report and review of the literature

AU - Korphaisarn, Krittiya

AU - Loree, Jonathan M.

AU - Nguyen, Van

AU - Coulson, Ryanne

AU - Holla, Vijaykumar

AU - Litzenburger, Beate C.

AU - Chen, Ken

AU - Mills, Gordon

AU - Maru, Dipen M.

AU - Meric-Bernstan, Funda

AU - Shaw, Kenna R.Mills

AU - Kopetz, Scott

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial response that lasted 27 months. Mutational status was extensively evaluated to identify potential alterations that might play a role as predictive markers for this unusual event. A poorly characterized but nontransforming mutation in Fms-like tyrosine kinase 4 (FLT4) was present in the tumor. Prior to and at the time of clinical progression, we found amplification of fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR), loss of the FLT4 mutation, and gain of KIT proto-oncogene receptor tyrosine kinase (KIT) G961S suggesting potential roles in acquired resistance.

AB - We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due to a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, regorafenib was given in the third line setting. Surprisingly, the patient had a prolonged partial response that lasted 27 months. Mutational status was extensively evaluated to identify potential alterations that might play a role as predictive markers for this unusual event. A poorly characterized but nontransforming mutation in Fms-like tyrosine kinase 4 (FLT4) was present in the tumor. Prior to and at the time of clinical progression, we found amplification of fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR), loss of the FLT4 mutation, and gain of KIT proto-oncogene receptor tyrosine kinase (KIT) G961S suggesting potential roles in acquired resistance.

KW - Biomarker

KW - Metastatic colorectal cancer

KW - Regorafenib

KW - Response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85029097095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029097095&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18357

DO - 10.18632/oncotarget.18357

M3 - Article

VL - 8

SP - 57882

EP - 57888

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -